- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Accretion Pharmaceuticals Limited — Updates, 17-11-2025: Press Release
17-11-2025 | 06:10 pm
17-11-2025 | 06:10 pm
Accretion Pharma's H1 FY26 saw revenue surge 135.59% to ₹43.74 Cr, EBITDA 62.94% to ₹7.07 Cr, and PAT 92.81% to ₹4.75 Cr. Growth fueled by IPO-backed capacity expansion and diversified product offerings. Expanded global reach with new market approvals for African exports.
No comments yet. Be the first to comment!